The pooled estimate from the studies suggested that the addition of testosterone to HT regimens improved sexual function scores for postmenopausal women .
A significant adverse effect was a decrease in high-density lipoprotein ( HDL ) cholesterol levels .
However , there is evidence that adding testosterone to HT has a beneficial effect on sexual function in postmenopausal women .
There was a reduction in HDL cholesterol associated with the addition of testosterone to the HT regimens .
It is , therefore , difficult to estimate the effect of testosterone on sexual function in association with any individual hormone treatment regimen
BACKGROUND : The value of adding testosterone to hormone therapy ( HT ) for the management of peri- and postmenopausal women is controversial and has not been systematic ally review ed .
OBJECTIVES : To determine the benefits and risks of testosterone therapy for peri- and postmenopausal women taking hormone therapy .
Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women.
OBJECTIVE Little is known about metabolic effects of testosterone treatment in postmenopausal women . The aim of the study was to compare the treatment effects of testosterone , estrogen , and testosterone plus estrogen on insulin sensitivities , body compositions , and lipid profiles in healthy postmenopausal women . DESIGN An open , r and omized clinical study with parallel group comparison . SETTING Women 's health clinical research unit at a university hospital . PATIENT(S ) Sixty-three naturally postmenopausal women participated in the study . INTERVENTION(S ) The participants were r and omly assigned to 3 months of treatment with testosterone undecanoate ( 40 mg every second day ) , estradiol valerate ( 2 mg daily ) , or the combination of both . MAIN OUTCOME MEASURE(S ) Insulin sensitivity assessed by euglycemic hyperinsulinemic clamp , body composition , and serum lipids . RESULT ( S ) Insulin-induced glucose disposal was reduced by approximately 20 % after treatment with testosterone alone , and after the combined treatment , but not by estrogen alone . Body weight , but not total body fat , increased significantly by about 1 kg in all groups . Lean body mass was significantly increased in the group of combined treatment and tended to be increased by testosterone alone . High-density lipoprotein (HDL)-cholesterol decreased significantly by testosterone treatment . In contrast , HDL-cholesterol increased , whereas low-density lipoprotein (LDL)-cholesterol and lipoprotein-(a ) [ Lp(a ) ] decreased with estradiol treatment . CONCLUSION ( S ) We conclude that 3 months of treatment with testosterone undecanoate in postmenopausal women induces insulin resistance and an adverse serum lipid profile but may increase lean body mass
The pooled estimate from the studies suggested that the addition of testosterone to HT regimens improved sexual function scores for postmenopausal women .
A significant adverse effect was a decrease in high-density lipoprotein ( HDL ) cholesterol levels .
However , there is evidence that adding testosterone to HT has a beneficial effect on sexual function in postmenopausal women .
There was a reduction in HDL cholesterol associated with the addition of testosterone to the HT regimens .
It is , therefore , difficult to estimate the effect of testosterone on sexual function in association with any individual hormone treatment regimen
BACKGROUND : The value of adding testosterone to hormone therapy ( HT ) for the management of peri- and postmenopausal women is controversial and has not been systematic ally review ed .
OBJECTIVES : To determine the benefits and risks of testosterone therapy for peri- and postmenopausal women taking hormone therapy .